||5R03CA150136-02 Interpret this number
||Validating Cancer Risk Models: a Pilot Study to Evaluate Cost-Efficient Methods
DESCRIPTION (provided by applicant): Validating Cancer Risk Models: a Pilot Study to Evaluate Cost-efficient Methods Abstract To facilitate targeted cancer prevention strategies and help patients weigh the costs and benefits of genetically tailored interventions, we need statistical models that provide accurate and precise projections of a person's risk of developing a given adverse outcome. Such models must be evaluated using cohort data on individuals at risk of the outcome. The ideal evaluation would genotype all subjects in a large cohort, use the genotypes to assign risks to all cohort members, and then relate assigned risks to subsequent outcomes. However such complete genotyping is too costly to be feasible. Our goal here is to test two new cost-effective methods for evaluating the added value of genetic covariates. The first is a case-cohort design that genotypes only a subset of the cohort members. The second uses case-control data and Bayes Rule to estimate the amount of increased precision gained with genotyping. Our goal is to use cohort data from the California Teachers Study (CTS) and population-based case-control data to test the two methods. We will do so by evaluating existing risk models for cancers of the ovary and breast using data from: a) all CTS subjects; b) a subset of CTS subjects in a case- cohort design; and c) subjects from a case-control study. We will use BRCAPRO scores as surrogates for pathogenic mutations of BRCA1 and BRCA2. This will allow us to compare inferences using (b) and (c) with those from (a), which will form the gold standard.
PUBLIC HEALTH RELEVANCE: Project Narrative To facilitate targeted cancer prevention strategies and help patients weigh the costs and benefits of genetically tailored interventions, we need statistical models that provide accurate and precise projections of a person's risk of developing a given adverse outcome. The goal of this project is to test two new cost-effective methods for evaluating the value of adding genetic covariates to these models using data from studies of cancers of the breast and ovary.
Two-stage sampling designs for external validation of personal risk models.
, Halpern J.
Statistical methods in medical research, 2016 08; 25(4), p. 1313-29.
Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype.
, McGuire V.A.
, Felberg A.
, Sieh W.
, Whittemore A.S.
, Longacre T.A.
The American journal of surgical pathology, 2012 Aug; 36(8), p. 1170-7.